Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jørgen Nyhus

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Expert Opinion on Biological Therapy|March 10, 2004
Novel peptide-based HIV-1 immunotherapyMaja A Sommerfelt, Jørgen Nyhus, Birger Sørensen
AIDS Research and Human Retroviruses|December 19, 2002
Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapyBirgitta Asjö, Helen Stavang, Birger Sørensen, et al.
AIDS (London, England)|February 14, 2006
Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cellsAnne-Marte B Kran, Birger Sørensen, Maja A Sommerfelt, et al.
Vaccine|November 18, 2005
Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)Jørgen Nyhus, Anne-Marte Bakken Kran, Maja A Sommerfelt, et al.
AIDS (London, England)|April 2, 2005
Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemiaDag Kvale, Anne-Marte Bakken Kran, Maja A Sommerfelt, et al.
AIDS (London, England)|September 9, 2004
HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)Anne-Marte B Kran, Birger Sørensen, Jørgen Nyhus, et al.
Vaccine|June 21, 2005
Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunizationAnne-Marte B Kran, Maja A Sommerfelt, Birger Sørensen, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Expert Opinion on Biological Therapy|March 10, 2004
Novel peptide-based HIV-1 immunotherapyMaja A Sommerfelt, Jørgen Nyhus, Birger Sørensen
AIDS Research and Human Retroviruses|December 19, 2002
Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapyBirgitta Asjö, Helen Stavang, Birger Sørensen, et al.
AIDS (London, England)|February 14, 2006
Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cellsAnne-Marte B Kran, Birger Sørensen, Maja A Sommerfelt, et al.
Vaccine|November 18, 2005
Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)Jørgen Nyhus, Anne-Marte Bakken Kran, Maja A Sommerfelt, et al.
AIDS (London, England)|April 2, 2005
Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemiaDag Kvale, Anne-Marte Bakken Kran, Maja A Sommerfelt, et al.
AIDS (London, England)|September 9, 2004
HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)Anne-Marte B Kran, Birger Sørensen, Jørgen Nyhus, et al.
Vaccine|June 21, 2005
Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunizationAnne-Marte B Kran, Maja A Sommerfelt, Birger Sørensen, et al.
Pageof 1